Meta Pixel

News and Announcements

Diversified Crypto Fund Performs Substantially Better Than Many Crypto Portfolios

  • Published July 28, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Boston Trading Co. is a diversified crypto fund (Bostoncoin) that provides easy access to crypto for individuals, retail investors and superannuation/SMSF’s/401K/RothIRA/retirement funds.

Investors have received returns of 366% per year on average for four years in a row, outperforming Bitcoin for six years. Since 2016, the Bostoncoin portfolio has included 30 to 50 crypto tokens plus tech stocks, making it easier for investors to have a safe and secure diversified crypto portfolio. 

Register Interest

View Deal Room

Portfolio Update

June 30th 2022

DART NAV 82.1310282

DART price 90.344131

One of the larger holdings in the DARTcoin portfolio is down massively; here is why Boston Trading is not panicking.

The Fund bought heavily into ThorChain (RUNE) when it was $0.50. It rocketed all the way up to $14 for almost 3000% gains. With the advent of crypto winter, RUNE has fallen to $1.85; losing almost 90% of its previous value, but the price is still 300% higher than when they first bought it. Boston Trading still has faith in the project and hopes to see it one day exceed its previous high.

The Bostoncoin diversified portfolio has fared better than many other crypto portfolios, due to its sensible diversification and lack of leverage. Whilst 3AC dropped 50-80% with Terra/Luna, Bostoncoin only slipped around 2.5%. The Fund continues to monitor the markets, rebalance as appropriate, and add to their positions when the price is low. Similar to grandaddy Bitcoin, the Bostoncoin portfolio is down for the year, but has more than doubled in the last two years.

Price updates for Bostoncoin, POLLYcoin, and DARTcoin will continue in the newsletters and the blog, and are also featured on mutual fund aggregation service Morningstar

Until next time, do as the wealthy do: get good advice from a professional, think long-term, and be bold when others are afraid. 

Register Interest

Capital Insights
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t

The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.

Capital Insights
Following the Billions: Where the Hyperscalers are Betting on the Future

The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.

Join over 45,000+ sophisticated investors

Join Now